Volumetric Modulated Arc Therapy (VMAT) techniques for fractioned stereotactic brain radiotherapy (FSBRT) can achieve highly conformal dose distribution to intracranial lesions. However, they can potentially increase the dose to hippocampus (H) causing neurocognitive toxicity during the first four months after irradiation. The purpose of this study was to assess the feasibility of hippocampal-sparing (HS) treatment plans in 22 patients with brain metastasis treated with VMAT technique. Firstly, we retrospectively analyzed hippocampal doses in all 22 VMAT original (not hippocampal-sparing, NHS) plans. Plans with hippocampal dose exceeding constraints (9 out of 22) were re-planned considering dose constraints on the hippocampus (H) and on hippocampal avoidance zone (HAZ) generated using 5 mm isotropic margin to the hippocampus. Conformity (CI) and homogeneity indexes (HI) on the target and MUs, were maintained as close as possible to the original plans. Mean CI NHS and CI HS obtained were: 0.79 AE 0.11 and 0.81 AE 0.10, respectively (P = 0.75); mean HI NHS and HI HS were 1.05 AE 0.02 and 1.04 AE 0.01 respectively (P = 0.72). In both sets of plans, the mean MU values were similar: 1033 AE 275 and 1022 AE 234 for NHS and HS respectively. In HS plans, the mean hippocampal dose was decreased by an average of 35%. After replanning, the D max (21.3 Gy) for HAZ and H was met by 45% (4/9) and 78% (7/9) of the NHS plans, respectively. The worst results were obtained for cases with target volumes extention closer than 12 mm to H, because of the difficulty to spare hippocampus without compromising target coverage. After replanning D 40% constraint value (7.3 Gy) was met by all the 9 NHS plans. In conclusion, this study suggests that an hippocampal-sparing approach to FSBRT is feasible resulting in a decrease in the dose to the hippocampus without any loss in conformity or increase in treatment time. 
| INTRODUCTION
Hippocampal injuries play a fundamental role both in short and longterm memory loss and cognitive impairment. 1, 2 Cranial irradiation can induce hippocampus damage, as suggested by some studies. [3] [4] [5] [6] [7] [8] [9] In particular, cognitive impairment caused by whole brain irradiation (WBRT) has been investigated. 10 These studies suggest that radiation-induced neurocognitive toxicity occurs after irradiating neural stem cells of the hippocampus, potentially compromising patients quality of life (QoL).
WBRT has long been considered the mainstay treatment for patients with multiple brain metastases; nowadays, due to innovative technologies, fractioned stereotactic brain radiotherapy (FSBRT) and radiosurgery (SRS) can represent valid alternative therapeutic options to WBRT 11, 12 allowing a better sparing of organs at risk, an improved outcome, and an increase in life expectancy; as a consequence, late onset radiation induced neurological sequels on hippocampi could be revealed in the course of life. Moreover, being the hippocampus very often close to the target, it could receive very high doses in extreme hypofractionated FSBRT treatments. Despite the large number of patients treated with these techniques, hippocampus is not routinely considered among organs at risk and the few clinical data available are not able to establish the correlation between dose on the hippocampus and cognitive effects. Results of the phase II RTOG 0933 study, 13 show that some benefit in neuro-cognitive functioning is achieved by hippocampal-sparing in brain radiotherapy; however, phase III trial studies are necessary to validate the approach and confirm these findings. In spite of the paucity of clinical data, many authors focus on the feasibility of hippocampal-sparing (HS) treatment plans. They applied the HS approach to WBRT followed by a radio-surgical boost or WBRT and simultaneous integrated boost treatments using highly conformal techniques such as IMRT, helical tomotherapy or VMAT [14] [15] [16] [17] [18] [19] demonstrating that HS plans were effectively able to spare the commonly delineated OARs including the hippocampus, while maintaining the same dose coverage and homogeneity of target volumes as the original ones. In these studies, the reduction in mean hippocampus dose was used as parameter to evaluate the appropriateness of the HS plans.
With regard to issues mentioned above, we conducted a retrospective feasibility study which consisted in elaborating HS plans for 22
FSBRT patients treated with VMAT technique maintaining the same coverage and homogeneity on the targets as the original plans. The hippocampus was firstly retrospectively delineated on the 22 plans and the corresponding dose-volume histograms (DVHs) were evaluated. Plans exceeding dose constraints for the hippocampus, were replanned introducing in the inverse planning module the dose volume constraints reported in literature. 7, 13 The reduction in mean hippocampal dose in the new plans compared to the original plans, was evaluated.
| MATERIALS AND METHODS

2.A | Study design
The present study was a theoretical planning exercise aimed to test HS hippocampal sparing planning technique in FSBRT. We selected cases planned and treated using a VMAT technique without considering hippocampus as OAR; hippocampus was retrospectively delineated and hippocampus dose constraints were evaluated. To test HS VMAT feasibility, cases with hippocampus exceeding dose limits were re-planned respecting original conformity and homogeneity indices. The Agility multileaf collimator (Elekta AB, Stockholm, Sweden) had 160 leaves of projected width 0.5 cm at the isocenter. Maximum leaf speed was 3.5 cm/s.
2.B | Patients and methods
To improve dose calculation accuracy for smaller lesions, the planning system was accurately extrapolated down to a 1 9 1 cm 2 field size. The plans consisted in two full coplanar arcs and additional non-coplanar partial arches were added to the two coplanar arcs with a couch angle chosen to avoid organs at risk. The dose normalization was chosen to ensure 95% of PTV volume coverage by 98% of prescribed dose (PD) for all of VMAT plans. In order to achieve better PTV coverage and lower OARs dose values, all VMAT plans were inversely planned optimizing leaf and gantry rotation speed and dose rate as free parameters. In case of irradiation of multiple lesions, the isocenter was automatically located at the center of mass of the lesions.
CBCT was performed daily before each treatment session to evaluate set-up errors. CBCT acquisition volume (clip-box) was determined to include whole PTV and OARs. The 3D-3DCBCT-CT planning scan co-registration was performed using the Gray level algorithm.
2.C | Retrospective hippocampus study
The Hippocampus (H) was retrospectively delineated on the original plans by a radiation oncologist on gadolinium contrast-enhanced T1-weighted MRI. Delineation was performed on axial images using the RTOG 0933 atlas 20 as reference. Afterwards, the contours in sagittal, coronal, and axial projections were revised by a neuroradiologist. A hippocampal avoidance zone (HAZ) was generated adding an isotropic 5 mm margin. The maximum dose (D max ) and dose to 100% of hippocampus volume (D 100% ) were documented for all VMAT plans, according to the RTOG 0933 dosimetric compliance criteria. 13 Moreover, the dose to 40% of hippocampus volume (D 40% ) was considered. 7 Since RTOG hippocampal constraints were defined for a prescribed dose of 30 Gy in ten fractions, they were converted to biologically equivalent doses in 2 Gy fractions (EQD2). As the D 40% constraint was more restrictive than D 100% , the latter was no longer considered in this study.
Due to the alternative fractionation FSBRT schema, the analysis of DVHs was performed, for all the OARs, reconverting all dose values to equivalent doses in 2-Gy fractions assuming an a/b ratio of 2 Gy.
In case original VMAT plans exceeded hippocampal constraints (non-hippocampal-sparing, NHS), HS plans were generated. The HS plans were elaborated following the same arc optimization systematic strategy as NHS regarding objectives, weights, and MU limit.
Hippocampal constraints have been applied on HAZ. In addition, the distance between HAZ and the adjacent lesion was measured.
The plan analysis included the evaluation of all the other OARs doses.
Dose delivery accuracy of all plans was assessed by measuring the 3D dose distributions with OCTAVIUS detector 729 device (PTW, Freiburg, Germany) and the agreement between measured and calculated dose profiles was checked using the gamma passing rate of 3% local dose (LD) and 3 mm distance to agreement (DTA) with a 10% threshold.
2.D | Dosimetric evaluation of VMAT plans
Dosimetric evaluation of both NHS and HS plans was carried out by calculating conformity and homogeneity indexes. Healthy brain mean dose as a surrogate of the integral dose for said tissue 21 was also evaluated.
The conformity index CI 22 was defined as:
where V T,pi was the volume of the target covered by the prescription isodose, V T was the target volume, and V pi was the volume of the prescription isodose. The homogeneity index (HI), 23 Tables 4 and 5 and those reported in Table 2 , it can be deduced that the constraints were not respected in the case of the minimum hippocampus-targets distance less than 12 mm. The closer hippocampus is to the target, the harder is to reduce the maximum dose without compromising target coverage.
A different result was obtained for D 40%. After re-planning, D 40%
constraint value (7.3 Gy) was met for all six NHS plans that originally did not comply for both H and HZA independent from the distance of the hippocampus from the target. it slightly touches HAZ (HS plan) only, with a greater dose sparing for both HZA and H.
All treatment plans presented gamma passing rate of at least 91% (LD = 3%, DTA = 3 mm). suggest the "non-applicability" of constraints to HAZ observing that sparing HAZ (hippocampus + 5 mm margin) poses a theoretical risk of disease progression in the margin region. 6 Taking into account these issues, we evaluated the feasibility of using VMAT to deliver FSBRT with hippocampal avoidance. Our results show that plan quality after hippocampal sparing is still well within the published standards of conformity and homogeneity.
| DISCUSSION
Mean NTMD NHS value was found comparable with mean NTMD HS (P = 0.73). This means that changing treatment parameters passing from NHS to HS plans maintaining the same target coverage does not increase the total energy deposited to the healthy brain.
In our retrospective analysis, we found that 9 of 22 cases had D max above the limits; 45% of them were recovered for HAZ (4/9 plans); one more plan was recovered for H (they passed from 6/9 to 7/9 plans!); dose values at 40% of volume (D 40% ) in HS plans were all recovered, both for H and HAZ. For HS plans presenting target adjacent to H (less than 12 mm) D max was not recovered, regardless the number of the lesions and dose prescription.
Even though mean doses in HS plans were not considered as constraints in the optimization strategy, the obtained values were in good agreement with the values reported in literature and close to the constraint proposed by several authors (6 Gy). [14] [15] [16] 18 However, it is difficult to compare our data with literature evidence, because dose prescription and fraction number are different, compared to similar studies regarding RT treatments for patients affected by 
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